

**Manuscript no. HAEMATOL/2010/038463 entitled "Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients"**

**Authors: Catherine Cordonnier, Montserrat Rovira, Johan Maertens, Oliver A Cornely, Per Ljungman, and Hermann Einsele**

**Information about the contributions of each person named as having participated in the study**

**1) Guarantor(s)**, i.e., person(s) who is (are) responsible for the integrity of the work as a whole:  
• Catherine Cordonnier; Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France; carlcard@club-internet.fr

According to the International Committee of Medical Journal Editors (ICMJE) ([http://www.icmje.org/ethical\\_1author.html](http://www.icmje.org/ethical_1author.html)): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 ..... Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

**2) Authors who participated in the conception of the study:**

The manuscript does not directly report clinical study data. However, the paper comments on the VOSIFI secondary prophylaxis study, and Catherine Cordonnier participated in the conception of that study.

**3) Design & Methods.** The following authors were responsible for specific investigations:

The manuscript does not directly report clinical study data. However, the paper comments on the VOSIFI secondary prophylaxis study, and the authors participated in the conduct of that study.

- Catherine Cordonnier, Montserrat Rovira, Johan Maertens, Oliver A Cornely, Per Ljungman, and Hermann Einsele were responsible for recruiting patients.
- Catherine Cordonnier, Montserrat Rovira, and Oliver A. Cornely were responsible for reviewing the clinical data in their function as data review board members.

**4) Results.** The following authors were responsible for specific portions of the results, including figures and tables

The manuscript does not directly report clinical study data and hence does not include a results section. However, the paper comments on the VOSIFI secondary prophylaxis study, and the authors participated in the conduct of that study and collected and interpreted the patient data. There are no figures and tables.

**5) Writing the manuscript.** The following authors were responsible for writing the manuscript:

- Catherine Cordonnier was responsible for drafting the manuscript.
- All authors were responsible for providing comments on the draft manuscript following critical review of the content.
- Catherine Cordonnier was responsible for revising the manuscript based on comments from all other authors.
- All authors were responsible for approving the final submitted version.

**6) Contributors Listed in Acknowledgments:**

Editorial support was provided by D. Wolf, of PAREXEL, and was funded by Pfizer Inc.